Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 856,908
  • Shares Outstanding, K 18,151
  • Annual Sales, $ 179,280 K
  • Annual Income, $ 17,490 K
  • EBIT $ 119 M
  • EBITDA $ 120 M
  • 60-Month Beta 1.11
  • Price/Sales 4.50
  • Price/Cash Flow 41.16
  • Price/Book 6.85

Options Overview Details

View History
  • Implied Volatility 85.97% (-1.77%)
  • Historical Volatility 112.13%
  • IV Percentile 56%
  • IV Rank 46.92%
  • IV High 127.55% on 04/16/25
  • IV Low 49.22% on 08/26/25
  • Expected Move (DTE 14) 6.16 (13.01%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 119
  • Volume Avg (30-Day) 391
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 4,301
  • Open Int (30-Day) 5,011
  • Expected Range 41.22 to 53.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.08
  • Number of Estimates 2
  • High Estimate 1.16
  • Low Estimate 0.99
  • Prior Year 0.80
  • Growth Rate Est. (year over year) +35.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.00 +39.35%
on 11/11/25
52.24 -9.30%
on 11/28/25
+19.00 (+66.95%)
since 11/04/25
3-Month
26.38 +79.61%
on 10/14/25
52.24 -9.30%
on 11/28/25
+7.25 (+18.07%)
since 09/04/25
52-Week
14.63 +223.86%
on 12/24/24
52.24 -9.30%
on 11/28/25
+20.89 (+78.86%)
since 12/04/24

Most Recent Stories

More News
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 47.38 (+0.36%)
Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

SOUTH SAN FRANCISCO, Calif. , Nov. 17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 47.38 (+0.36%)
Rigel to Present at the Jefferies Global Healthcare Conference in London

SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 47.38 (+0.36%)
Rigel: Q3 Earnings Snapshot

Rigel: Q3 Earnings Snapshot

RIGL : 47.38 (+0.36%)
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , Nov. 4, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 47.38 (+0.36%)
Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif. , Nov. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 47.38 (+0.36%)
Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2025 financial results after market close...

RIGL : 47.38 (+0.36%)
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS

RIGL : 47.38 (+0.36%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....

RIGL : 47.38 (+0.36%)
Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and...

RIGL : 47.38 (+0.36%)

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 50.07
2nd Resistance Point 49.29
1st Resistance Point 48.33
Last Price 47.38
1st Support Level 46.59
2nd Support Level 45.81
3rd Support Level 44.85

See More

52-Week High 52.24
Last Price 47.38
Fibonacci 61.8% 37.87
Fibonacci 50% 33.44
Fibonacci 38.2% 29.00
52-Week Low 14.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar